Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Sankyo Co., Ltd. engages in the manufacture and sale of pachinko and pachislot machines. It operates through the following segments: Pachinko Machines Business, Pachislot Machines Business, Ball Bearing Supply Systems Business, and Others. The Pachinko Machines Business segment produces and sells pachinko machines, machine gauges and its related parts. The Pachislot Machines Business segment markets pachislot machines and related parts. The Ball Bearing Supply Systems segment sells pachinko and pachislot ball feeders, card system equipment, and parlor-related equipment. The Others segment comprises of mobile content service, real estate, golf club operations, and sells general molding products. The company was established on April 12, 1966 and is headquartered in Tokyo, Japan.

Doheny Eye Institute is an American private company located in Los Angeles, CA. The firm provides eye care related research and education programs. Marissa Goldberg is currently the CEO of the company.\nThe company says this about itself: For more than 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinician-scientists and researchers are changing how people see �� and also how they think about the future of vision. Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best patient care, vision research, and education. This affiliation combines the strength, reputation, and distinction of two of the nation's top eye institutions to advance vision research, education, and patient care in California.

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Seoul National University Hospital (서울대학교병원) is one of the oldest and biggest hospitals in South Korea. It is a general and teaching hospital of Seoul National University's College of Medicine. Except SNUH Healthcare System Gangnam Center, all branches have an emergency department (ED).

BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Aliophtha is work on Research and development in the field of pharmaceutical products, including biological and biotechnological products, and manufacturing and commercialization of such products, research in the field of medical technology, and development, manufacture and distribution of medical device and products and related industries.

Topcon, their core business is founded on the surveying instruments they have manufactured since their founding in 1932 and ophthalmic & medical equipment they introduced to the market following World War II. Since then, they have expanded their business domains through a combination of M&A and alliances, including construction machinery control technology since 1994, precision GPS receivers since 2000, precision agriculture since 2006, and mobile control technology since 2007. Today, the world is facing an increase in eye diseases due to global population aging, food shortages caused by global population increase, global infrastructure demands and a shortage of engineering personnel to meet that demand, and continued infrastructure deterioration. In the domains of healthcare, agriculture, and infrastructure, they embraces the slogan "Topcon for Human Life" as they work to expand their business by applying Topcon solutions towards resolving societal challenges.

Kookmin University Industry-Academic Cooperation is an independent academic corporation.

DOSE Medical Corp. is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration (AMD) and diabetic macular edema.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Using the Principal Investigator's background in epidemiology and clinical ophthalmology, the Zietchick Research Institute is currently seeking new treatments for eye diseases that primarily target mothers and infants.

Shenyang Shuangding Pharmaceutical Co., Ltd., established on 2002-12-17, Business range includes tablet,Granules,hard capsule,small volume injection,API,nose drops,Freeze-dried powder injection,dry suspension,hygiene products(skin,Mucous membrane hygiene products)Production,Research and development of medical technology related to the above products,technology transfer,Technical Services(Except for projects prohibited by laws and regulations and projects that should be approved but have not been approved);Agricultural product acquisition(Except for projects that should be approved but not approved);Own property rental.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Alcon Research Ltd., a subsidiary of Nestl�� SA, is a company headquartered in Huntington, WV, that manufactures optical goods.